UPC Universe Pharmaceuticals INC Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1809616 · Fiscal year ends 09/30
Financial factors as of 2025-09-30 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-22.4%
TTM net income YoY57.9%
TTM EPS YoY98.7%
Revenue 3-yr CAGR663.4%
Net income 3-yr CAGR—
Margins
Gross margin35.3%
Operating margin-16.3%
Net margin-20.6%
FCF margin-29.8%
EBITDA margin-13.4%
Returns
ROE-7.2%
ROA-5.4%
ROIC (approx.)-12.0%
Asset turnover0.26x
Leverage & solvency
Liabilities / assets19.0%
Debt / equity0.00x
Current ratio4.07x
Interest coverage-10.08x
Cash quality & payout
Operating cash flow / net income1.38x
Accruals ratio2.0%
Payout ratio—
Capex / revenue1.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 | FY20232023-09-30 | FY20222022-09-30 | FY20212021-09-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $17.86B | $23.02B | $32.31B | $40.14M | $47.98M |
| Cost of revenue | $11.56B | $16.95B | $21.99B | $18.25M | $22.66M |
| Gross profit | $6.30B | $6.07B | $10.32B | $21.89M | $25.33M |
| R&D expense | $671.76M | $3.03B | $4.86B | $7.64M | $5.47M |
| SG&A expense | $3.75B | $2.89B | $2.64B | $2.18M | $3.30M |
| Operating income | -$2.92B | -$8.02B | -$3.97B | -$7.02M | $13.59M |
| Interest expense | $289.38M | $304.52M | $190.18M | $162,400 | $101,604 |
| Pretax income | -$3.67B | -$8.12B | -$4.33B | -$7.09M | $13.68M |
| Income tax | — | $606.70M | $2.25B | $815,322 | $2.36M |
| Net income | -$3.67B | -$8.73B | -$6.58B | -$7.91M | $11.32M |
| EBITDA | -$2.40B | -$7.53B | -$3.46B | -$6.49M | $14.04M |
| EPS (basic) | -8.06 | -626.96 | -1,089.21 | -1,309.11 | 3.58 |
| EPS (diluted) | -8.06 | -626.96 | -1,089.21 | -1,309.11 | 3.58 |
| Weighted avg. shares (diluted) | 455,871 | 13,920 | 6,042 | 6,042 | 3.16M |
| Balance sheet | |||||
| Cash & equivalents | $33.59B | $29.50B | $5.29B | $5.71B | $8.08M |
| Short-term investments | — | — | $13.22M | $13.15M | $13.73M |
| Receivables | $13.01B | $12.91B | $11.01M | $15.18M | $15.57M |
| Inventory | $2.19B | $1.74B | $3.34M | $2.21M | $2.46M |
| Current assets | $53.60B | $51.64B | $25.27M | $41.51M | $50.48M |
| PP&E, net | $3.58B | $3.57B | $3.70M | $4.25M | $4.68M |
| Intangibles | $296.79M | $262.88M | $148,584 | $157,451 | $148,584 |
| Total assets | $69.30B | $67.95B | $41.72M | $59.54M | $70.14M |
| Current liabilities | $13.17B | $20.31B | $13.75M | $13.10M | $11.21M |
| Short-term debt | $2.11B | $5.86B | $5.48M | $3.94M | $4.33M |
| Total liabilities | $13.17B | $22.45B | $13.75M | -$35.27B | $23.15M |
| Shareholders' equity | $56.13B | $45.50B | $27.97B | $35.33B | $46.99M |
| Shares outstanding | 563,338 | 42,880 | 6,062 | 3.62M | 21.75M |
| Cash flow statement | |||||
| Operating cash flow | -$5.05B | -$9.51B | $1.12B | -$1.30M | -$2.06M |
| Capital expenditure | $266.77M | $208.32M | $44.17M | $93,703 | $444,505 |
| Free cash flow | -$5.32B | -$9.72B | $1.07B | -$1.40M | -$2.50M |
| Investing cash flow | -$341.81M | -$361.29M | -$44.17M | -$3.91M | -$27.06M |
| Financing cash flow | $9.73B | $33.95B | -$1.39B | $3.32M | $26.58M |
| Depreciation & amortization | $517.43M | $485.73M | $508.79M | $533,949 | $446,878 |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.